What is tubular carcinoma of the breast?
Tubular carcinoma is an uncommon type of invasive breast cancer with one of the best outlooks of any breast cancer. It takes its name from its appearance under the microscope: the cancer cells form small, well-shaped tubes that resemble normal breast ducts. This orderly pattern reflects a slow-growing, low-grade tumour.
Tubular carcinoma is a special type of breast cancer. It is distinguished from the far more common invasive ductal carcinoma of no special type. To be called pure tubular carcinoma, most of the tumour, usually at least 90%, must be made of these tubules. Tumours with fewer tubules are described as mixed and behave more like ordinary breast cancers.
These cancers are usually small, are often found on screening mammograms before they can be felt, and rarely spread to the lymph nodes. Almost all are hormone receptor-positive and HER2-negative (Sakhri et al., 2023). In a large American registry analysis, people with tubular carcinoma lived longer than those with low-grade ductal cancer (Romano et al., 2015).
Treatment usually involves surgery, often breast-conserving, with radiotherapy and hormone therapy. Chemotherapy is rarely needed.
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | Special type of invasive breast carcinoma |
| Share of breast cancers | About 1-2% in general; higher in screened groups (8.4% in one series) |
| Typical age | Usually over 50 |
| How it is found | Most often on a screening mammogram |
| Typical size | Small, usually under 2 cm |
| Receptor status | Oestrogen receptor-positive, HER2-negative in almost all cases |
| Lymph node spread | Uncommon; about 6% in a large registry |
| Main treatment | Surgery, radiotherapy if the breast is kept, hormone therapy |
| Outlook | Excellent; 10-year breast cancer-specific survival around 97% |
2. Types
| Type | Description | Behaviour |
|---|---|---|
| Pure tubular carcinoma | At least 90% tubules | Excellent outlook |
| Mixed tubular carcinoma | Tubules in 50-90% of the tumour, mixed with ductal cancer | Behaves more like ordinary ductal cancer of similar grade |
| Tubulolobular carcinoma | Tubules with features of lobular cancer | Usually low grade; may involve both breasts more often |
Associated changes in the breast
Tubular carcinoma often occurs alongside other low-grade changes in the breast. These belong to the “low-grade breast neoplasia family”.
| Associated change | Meaning |
|---|---|
| Flat epithelial atypia | Mildly abnormal lining cells; frequently seen with tubular carcinoma (Romano et al., 2015) |
| Atypical ductal hyperplasia | Abnormal cell growth that raises cancer risk |
| Low-grade ductal carcinoma in situ | Non-invasive cancer within the ducts |
| Lobular neoplasia | Abnormal cells in the milk-producing lobules |
In one radiology series, other lesions, most often ductal carcinoma in situ, were found in the removed tissue in about two-thirds of patients (Mitnick et al., 1999).
Tubular carcinoma compared with other low-grade breast cancers
| Feature | Tubular carcinoma | Grade 1 ductal cancer |
|---|---|---|
| Microscopic pattern | Open, angulated tubules with one cell layer | Mixture of patterns |
| Hormone receptors | Almost always positive | Usually positive |
| Lymph node spread | Rare | More frequent |
| Survival in SEER data | Better | Very good, but lower than tubular |
3. Causes and risk factors
Tubular carcinoma shares the general risk factors for hormone receptor-positive breast cancer.
| Risk factor | Notes |
|---|---|
| Increasing age | Most cases occur after 50 |
| Female sex | Very rare in men |
| Long exposure to oestrogen | Early periods, late menopause, few or no pregnancies |
| Hormone replacement therapy | Combined HRT increases risk |
| Family history | First-degree relatives with breast cancer |
| Previous atypical hyperplasia | Increased risk of low-grade cancers |
| Alcohol and excess weight after menopause | Modestly raise risk |
4. How does it look
On imaging
| Test | Typical finding |
|---|---|
| Mammogram | Small, spiky (spiculated) mass or an area of distortion, sometimes with fine calcifications |
| Ultrasound | Small, irregular, dark area with shadowing |
| MRI | Used in selected cases, for example to check the extent |
In a series of 78 tubular carcinomas, mammography detected most, about 87%. Ultrasound found every lesion in which it was used, including several that the mammogram had missed. Only about 1 in 5 tumours could be felt (Mitnick et al., 1999).
Under the microscope
| Feature | Description |
|---|---|
| Tubules | Open, oval or angular tubes, lined by one layer of cells |
| Cells | Small and uniform, with few dividing cells |
| Missing outer layer | The myoepithelial layer present around normal ducts is absent |
| Surrounding tissue | Reactive, fibrous stroma |
| Grade | Almost always grade 1 |
Because the tubules look so close to normal, the pathologist may use special stains to show that the outer myoepithelial layer is absent, which confirms invasion.
Screening and tubular carcinoma
Because tubular carcinomas are small and slow-growing, they are often found through mammographic screening. In screened groups they form a larger share of the cancers detected than in women who come to a clinic with symptoms. Finding them early contributes to their very good results.
5. Symptoms
Common features
- No symptoms, with the cancer found on a screening mammogram
- A small, firm lump in some women
Less common features
| Feature | Notes |
|---|---|
| Skin dimpling | Due to the fibrous, spiky nature of the tumour |
| Nipple changes | Uncommon |
| Lump in the armpit | Rare, as lymph node spread is uncommon |
| Breast pain | Not usually caused by cancer, but should be checked if new and persistent |
When to seek medical advice
See your doctor if you notice a new lump, a change in breast shape, skin dimpling or nipple changes. Attend breast screening when invited.
6. Diagnosis
| Test | Purpose |
|---|---|
| Clinical breast examination | Checks the breasts and armpits |
| Mammogram | Main imaging test |
| Breast ultrasound | Assesses the lesion and the armpit |
| Core needle biopsy | Confirms cancer and type |
| Hormone receptor and HER2 tests | Guide treatment |
| Axillary ultrasound | Looks for abnormal nodes |
| Staging scans | Usually not needed for small tumours |
Core biopsy is preferred
| Biopsy type | Sensitivity in Mitnick series | Comment |
|---|---|---|
| Core needle biopsy | About 91% | Preferred method |
| Fine-needle aspiration | About 50% | Often inconclusive, as the cells look bland |
Tubular carcinoma can be difficult to recognise on a small sample because the cells look so normal. A benign condition called radial scar can also look similar on a mammogram and under the microscope. For this reason, the full tumour is examined after surgery to confirm that it is pure tubular carcinoma.
7. Treatment
Surgery
| Option | Notes |
|---|---|
| Breast-conserving surgery (wide local excision) | Usually suitable, as tumours are small |
| Mastectomy | For larger areas, several tumours or patient preference |
| Sentinel lymph node biopsy | Usual way to check the armpit nodes |
| Axillary lymph node dissection | Only if the sentinel node shows significant spread |
The role of armpit surgery has been debated. A SEER study of over 5,600 patients found nodal spread in about 6%, including about 5% of tumours of 2 cm or less. Survival was very high in both groups.
The authors suggested axillary surgery may still be considered, even for small tumours (Chen et al., 2019). In current practice, this usually means sentinel node biopsy rather than full dissection.
Radiotherapy
| Situation | Approach |
|---|---|
| After breast-conserving surgery | Usually recommended; omission may be discussed for older women taking hormone therapy |
| After mastectomy | Rarely needed |
| Partial breast radiotherapy | An option for small, low-risk tumours |
Hormone therapy
| Drug | Who it suits |
|---|---|
| Tamoxifen | Pre-menopausal and some post-menopausal women |
| Aromatase inhibitors (anastrozole, letrozole, exemestane) | Post-menopausal women |
| Ovarian suppression | Selected younger women |
Hormone therapy is usually taken for at least 5 years. For very small, node-negative pure tubular cancers, the benefit may be small, and the decision is often shared between the patient and the doctor.
Chemotherapy
Chemotherapy is rarely needed. It may be considered when lymph nodes are clearly involved, the tumour is large, or the tumour is of mixed type. In a small series, only one of seven women received it (Sakhri et al., 2023).
Recovery timeline
| Stage | What to expect |
|---|---|
| Day of surgery | Most women go home the same day or the next day |
| First 2 weeks | Wound healing, mild discomfort, gentle arm exercises |
| 2-3 weeks after surgery | Results of the full tumour analysis and a treatment plan |
| 4-8 weeks after surgery | Radiotherapy begins, if planned |
| Radiotherapy | Usually 1-3 weeks of weekday sessions |
| Hormone therapy | Often started after radiotherapy and continued for years |
Treatment choices for older women
For women in their 70s and beyond with a small, node-negative, hormone-sensitive tubular carcinoma, treatment can often be lighter. Options include breast-conserving surgery followed by hormone therapy alone, without radiotherapy, or in some cases omitting sentinel node biopsy. These choices balance a small rise in the chance of the cancer returning in the breast against fewer hospital visits and side effects. Your team will discuss your general health and preferences.
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, bruising, change in breast shape, seroma |
| Sentinel node biopsy | Small risk of arm swelling and numbness |
| Radiotherapy | Tiredness, skin redness, breast firmness |
| Tamoxifen | Hot flushes, small risk of clots and womb lining changes |
| Aromatase inhibitors | Joint aches, bone thinning, hot flushes |
8. Outlook (prognosis)
| Measure | Result |
|---|---|
| 10-year breast cancer-specific survival (SEER) | About 97% |
| Survival compared with grade 1 ductal cancer | Longer (Romano et al., 2015) |
| Local recurrence | Low |
| Distant spread | Rare |
In a series of seven women with pure tubular carcinoma, no local or distant recurrence occurred during follow-up (Sakhri et al., 2023).
Factors that may affect the outlook
| Factor | Effect |
|---|---|
| Pure versus mixed type | Pure type does better |
| Size over 2 cm | Associated with lymph node spread |
| Lymph node involvement | Uncommon, but warrants fuller treatment |
| Age 65 or younger | Linked with node-positive disease in the SEER analysis |
9. Follow-up
| Follow-up | Typical schedule |
|---|---|
| Clinic review | Every 6-12 months for the first few years |
| Mammogram | Yearly, usually for at least 5 years, then via screening |
| Bone health checks | For women taking aromatase inhibitors |
| Gynaecological check | For abnormal bleeding while taking tamoxifen |
10. Living with tubular carcinoma
- Take hormone therapy as prescribed, and talk to your team about side effects
- Keep physically active; exercise can ease joint aches and tiredness
- Limit alcohol and keep a healthy weight
- Check your breasts regularly and report changes
- Look after your bones with vitamin D, calcium and weight-bearing exercise
- Wear a well-fitting, supportive bra while the wound heals
- Seek support from breast cancer charities and support groups
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is tubular carcinoma a real cancer? | Yes, it is invasive, but it has a very good outlook |
| Will I need chemotherapy? | Usually not |
| Can I keep my breast? | Most women can have breast-conserving surgery |
| Do I need radiotherapy? | Usually after breast-conserving surgery, though it may be omitted in some older women |
| Do I need hormone tablets? | Usually recommended, but the benefit is small in very low-risk cases |
| Can it come back? | It can, but recurrence is uncommon; report any new lump or change |
| Should my daughters be screened early? | Only if the family history suggests a higher risk; ask your team |
| Is it inherited? | Usually not |
| Can men get it? | Very rarely; treatment follows the same principles |
| Is it the same as a radial scar? | No; a radial scar is benign, though the two can look alike on a mammogram |
12. Questions to ask your care team
- Is my tumour pure or mixed tubular carcinoma?
- What size is it, and are my lymph nodes involved?
- Can I have breast-conserving surgery?
- Do I need radiotherapy and hormone therapy, and for how long?
- What are the side effects of the treatments you recommend?
- What follow-up will I have?
- Would I be suitable for partial breast or shorter radiotherapy?
- Is it safe to leave out any treatment in my situation?
Resources
- Chen, S.L. et al. (2019) ‘The role of axillary lymph node dissection in tubular carcinoma of the breast: a population database study’, Medical Science Monitor, 25, pp. 880-887.
- Mitnick, J.S. et al. (1999) ‘Tubular carcinoma of the breast: sensitivity of diagnostic techniques and correlation with histopathology’, American Journal of Roentgenology, 172(2), pp. 319-323.
- Romano, A.M. et al. (2015) ‘Tubular carcinoma of the breast: institutional and SEER database analysis supporting a unique classification’, Breast Disease, 35(2), pp. 103-111.
- Sakhri, S. et al. (2023) ‘Pure tubular carcinoma of the breast: a case series’, Journal of Medical Case Reports, 17(1), 284.
- National Cancer Institute (2026) Breast Cancer Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/breast/hp/breast-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.